Why are Immuno-Oncology compounds different?

Bookmark and Share
Published: 3 Dec 2013
Views: 4481
Prof. Enriqueta Felip - Vall d'Hebron University Hospital, Barcelona, Spain

ECC 2013 Immuno-Oncology Satellite Symposium supported by Bristol-Myers Squibb. Immuno-Oncology: the next new paradigm in cancer treatment?

Building upon the background of our current experience with the immuno-oncology compounds introduced in the prior presentations, Prof. Felip explores, from a clinical perspective, how these compounds differ from other modalities commonly used to treat patients with advanced cancer looking at the different response patterns and safety profiles.

To view the slides fullscreen click the square and arrows button at the bottom right of the player.